Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

Immune checkpoint inhibitors provide durable clinical responses in multiple difficult-to-treat tumor types. The tumor microenvironment, tumor immunogenicity, antigen presentation, and classic ...

A single β-lactam exposure rapidly drives stable multidrug resistance in RecA-deficient bacteria through an SOS-independent mechanism involving oxidative stress-induced mutagenesis and ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

CHENNAI, (IANS) – Vertically integrated pharma player Orchid Pharma Ltd said on February 23 that it will launch its Enmetazobactam drug in the US in the next couple of quarters.

Find out how Wegovy works for weight loss and the prevention of certain cardiovascular problems.

Mechanisms of disease articles from across Nature Portfolio The defects in molecular and cellular processes that constitute the triggers of specific pathologies are referred to as mechanisms of ...

Allecra – which licenses enmetazobactam from Indian drugmaker Orchid Pharma – said the approval has unlocked a five-year marketing exclusivity extension from the FDA as part of the GAIN Act ...

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections.

The overall mechanisms of action seem to be related to inhibiting the cellular machineries involved in the formation of complex biological structures such as DNA, RNA, proteins and the cell wall. In ...